← All trials
NCT05900531
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2022
- Primary completion
- May 3, 2023
- Completion date
- May 31, 2023
- First posted
- Jun 12, 2023
- Last posted
- Jun 12, 2023
- Enrollment
- 60
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kallyope Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.